Profile | GDS2987 / GI_27477080-A |
Title | Comparison of Rho kinase inhibitor and atorvastatin effects on primary cell lines |
Organism | Homo sapiens |
Sample | Title | Value | Rank |
---|---|---|---|
GSM214810 | HMVEC_vehicle_rep1 | 23.8 | 59 |
GSM215244 | HMVEC_vehicle_rep2 | 25.6 | 53 |
GSM215253 | HMVEC_vehicle_rep3 | 24.1 | 58 |
GSM215254 | HMVEC_atorvastatin_rep1 | 14.4 | 36 |
GSM215282 | HMVEC_atorvastatin_rep3 | 29.4 | 55 |
GSM215344 | HMVEC_atorvastatin_rep2 | 24 | 50 |
GSM215283 | HMVEC_atorvastatin_mevalonate_rep1 | ||
GSM215284 | HMVEC_atorvastatin_mevalonate_rep2 | 30.8 | 52 |
GSM215293 | HMVEC_atorvastatin_mevalonate_rep3 | ||
GSM215294 | HMVEC_SLx2119_rep1 | 19.3 | 55 |
GSM215295 | HMVEC_SLx2119_rep2 | 17.1 | 33 |
GSM215296 | HMVEC_SLx2119_rep3 | 15.4 | 26 |
GSM215297 | PASMC_vehicle_rep1 | 11.7 | 18 |
GSM215298 | PASMC_vehicle_rep2 | 23.5 | 35 |
GSM215310 | PASMC_vehicle_rep3 | 17.4 | 28 |
GSM215311 | PASMC_atorvastatin_rep1 | 46.3 | 61 |
GSM215312 | PASMC_atorvastatin_rep2 | 18.8 | 29 |
GSM215313 | PASMC_atorvastatin_rep3 | 10.5 | 16 |
GSM215324 | PASMC_atorvastatin_mevalonate_rep1 | 21.7 | 35 |
GSM215325 | PASMC_atorvastatin_mevalonate_rep2 | 33.8 | 54 |
GSM215326 | PASMC_atorvastatin_mevalonate_rep3 | 7.9 | 14 |
GSM215327 | PASMC_SLx2119_rep1 | 28.4 | 45 |
GSM215328 | PASMC_SLx2119_rep2 | 49.4 | 63 |
GSM215329 | PASMC_SLx2119_rep3 | 14.9 | 28 |
GSM215330 | Fibroblasts_vehicle_rep1 | 39.8 | 62 |
GSM215331 | Fibroblasts_vehicle_rep2 | 13.2 | 35 |
GSM215332 | Fibroblasts_vehicle_rep3 | 12.5 | 39 |
GSM215333 | Fibroblasts_atorvastatin_rep1 | 19.7 | 46 |
GSM215334 | Fibroblasts_atorvastatin_rep2 | 27.6 | 57 |
GSM215335 | Fibroblasts_atorvastatin_rep3 | 15 | 35 |
GSM215336 | Fibroblasts_atorvastatin_mevalonate_rep1 | 2.4 | 8 |
GSM215337 | Fibroblasts_atorvastatin_mevalonate_rep2 | 2.2 | 7 |
GSM215338 | Fibroblasts_atorvastatin_mevalonate_rep3 | 30.6 | 60 |
GSM215339 | Fibroblasts_SLx2119_rep1 | 18.4 | 47 |
GSM215340 | Fibroblasts_SLx2119_rep2 | 19.9 | 48 |
GSM215341 | Fibroblasts_SLx2119_rep3 |